<DOC>
	<DOCNO>NCT02120924</DOCNO>
	<brief_summary>The purpose study compare safety efficacy profile generic Azelaic Acid Gel , 15 % reference list Finacea® ( azelaic acid ) Gel , 15 % treatment moderate facial rosacea .</brief_summary>
	<brief_title>A Study Evaluate Safety Clinical Study Azelaic Acid Gel 15 % Patients With Moderate Facial Rosacea</brief_title>
	<detailed_description>FINACEA® ( azelaic acid ) GEL , 15 % contains azelaic acid , naturally occur saturate dicarboxylic acid proven anti-inflammatory effect , well anti-keratinizing antimicrobial action , although mechanism action rosacea well understood . This study conduct compliance protocol , Good Clinical Practices ( GCP ) applicable regulatory requirement ( ) . Marketed Intendis , Finacea® ( azelaic acid ) Gel , 15 % safe effective topical therapy use treatment moderate facial rosacea . Watson Laboratories , Inc. develop generic formulation azelaic acid 15 % gel current study design evaluate safety efficacy formulation .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Azelaic acid</mesh_term>
	<criteria>Healthy male nonpregnant female ≥18 yearsofage clinical diagnosis moderate facial rosacea . Patient must least eight fifty inflammatory facial lesion ( i.e. , papules/pustules ) ≤2 nodules face . For purpose study treatment evaluation , lesion limit facial treatment area include present nose . Lesions involve eye , scalp exclude count . Patients must persistent erythema face moderate ( Definite redness , easily recognize ) Severe ( Marked erythema ; fiery red ) . Patients must mild moderate score telangiectasia face Patients must definite clinical diagnosis moderate facial rosacea per IGE Patient must willing minimize external factor might trigger rosacea flareups ( e.g. , spicy food , thermally hot food drink , hot environment , prolong sun exposure , strong wind alcoholic beverage ) . Patient must general good health free clinically significant disease rosacea , might interfere study evaluation . Patient must willing able understand comply requirement study , apply medication instruct , return require treatment period visit , comply therapy prohibition , able complete study . Female Subjects childbearing potential ( exclude woman surgicallysterilized postmenopausal least 1 year ) , addition negative urine pregnancy test , must willing use acceptable form birth control study day first dose administration 30 day last administration study drug For purpose study follow consider acceptable method birth control : oral contraceptive , contraceptive patch , contraceptive implant , vaginal contraceptive , double barrier method ( e.g. , condom spermicide ) , contraceptive injection ( Depoprovera® ) , intrauterine device ( IUD ) , hormonal IUD ( Mirena® ) abstinence document second acceptable method birth control , patient become sexually active . Patients hormonal contraception must stabilize type least three month prior enrollment study must change hormonal contraception study . Patients use hormonal contraception stop must stop less three month prior study . A sterile sexual partner NOT consider adequate form birth control . All male patient must agree use accept method birth control partner , day first dose administration 30 day last administration study drug . Abstinence acceptable method birth control . Female partner use acceptable method birth control describe Item Number 10 . Patients use makeup must use brands/types makeup minimum period 14 day prior study entry must agree use makeup , brand/type , frequency use , throughout study . Pregnant lactate plan become pregnant study period . Presence skin condition face would interfere diagnosis assessment rosacea . Excessive facial hair ( e.g . beard , sideburn , moustache , etc . ) would interfere diagnosis assessment rosacea . History hypersensitivity allergy azelaic acid , propylene glycol component formulation . The use within 6 month prior baseline oral retinoids ( e.g . Accutane® ) therapeutic vitamin A supplement great 10,000 units/day ( multivitamin allow ) . The use estrogens oral contraceptive le 3 month prior baseline . The use within 1 month prior baseline : 1. topical retinoids face ; 2. systemic antibiotic know impact severity facial rosacea ( e.g. , contain tetracycline derivative , erythromycin derivative , sulfamethoxazole , trimethoprim ) ; 3. systemic corticosteroid ( Note : intranasal inhalational corticosteroid require washout maybe use throughout trial subject stable dose ) . Use within 2 week prior baseline : 1. topical corticosteroid ; 2. topical antibiotic ; 3. topical medication rosacea ( e.g. , metronidazole ) . Patients moderate severe rhinophyma , dense telangiectases ( score 3 , severe ) , plaquelike facial edema . Patients severe irritation grade erythema , dryness , scaling , pruritus , stinging/burning , edema . Ocular rosacea ( e.g. , conjunctivitis , blepharitis , keratitis ) sufficient severity require topical systemic antibiotic . A patient use sauna 2 week prior study entry study . Patients perform wax epilation face within 14 day prior baseline A patient history unresponsive topical azelaic acid therapy . A patient bacterial folliculitis . A patient consumes excessive alcohol , abuse licit illicit drug , condition could compromise patient 's ability comply study requirement . Patients engage activity involve excessive prolonged exposure sunlight weather extreme , wind cold . A patient clinically significant condition situation , condition study , opinion Investigator , would interfere study evaluation optimal participation study . A patient use topical azelaic acid therapy within 30 day baseline visit . Patients participate investigational drug study ( i.e. , patient treat Investigational Drug ) within 30 day prior baseline exclude study participation . Patients participate nontreatment study observational study registry study consider inclusion . Patients previously enrol study . Patients laser therapy ( telangiectasia condition ) , electrodessication phototherapy ( e.g. , ClearLight® ) facial area within 180 day prior study entry . Patients cosmetic procedure ( e.g. , facial ) may affect efficacy safety profile Investigational Product within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Moderate facial rosacea</keyword>
	<keyword>Azelaic acid</keyword>
	<keyword>Rosacea</keyword>
</DOC>